Investors Have a Chance to Join Kyverna Therapeutics Class Action Lawsuit

LOS ANGELES, Jan. 28, 2025 /PRNewswire/ — Investors with losses now have a chance to lead a securities fraud class action lawsuit against Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) KYTX.

Have You Lost Money Investing in Kyverna? Act Before FEBRUARY 7, 2025

Details of the Lawsuit
The complaint alleges that, connected to the Registration Statement from the Company’s February 2024 initial public offering, the defendants failed to reveal crucial information to investors. This includes (1) negative data from one of its clinical trials; (2) the risk associated with withholding such data; and (3) misrepresentations regarding the Company’s business and prospects being materially misleading at all times.

How to Get Involved or Learn More
If you would like more information about this lawsuit, or have questions regarding your rights, please contact us.
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles, California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

If you reach out via email, please provide your mailing address, phone number, and the number of shares purchased.

To join the class action, no immediate action is required. You may retain legal counsel of your choosing or choose to remain an absent class member.

This press release may be considered Attorney Advertising in some jurisdictions under applicable law and ethical rules.

Contact Information
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067

Charles Linehan
Email: [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website: www.glancylaw.com.

View original content to download multimedia: https://www.prnewswire.com/news-releases/kyverna-therapeutics-inc-kytx-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302361737.html

SOURCE Glancy Prongay & Murray LLP